3 results about "Auxin" patented technology

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

The invention discloses a high-activity hyaluronic acid-polypeptide conjugate as well as a preparation method and application thereof. The preparation method of the high-activity hyaluronic acid-polypeptide conjugate comprises the following steps: preparing aldehyde modified hyaluronic acid; the preparation method comprises the following steps: dissolving aldehyde modified hyaluronic acid in a buffer solution, adding auxin and sodium cyanoborohydride, and reacting; ethyl carbazate is added for a reaction; finally, the hyaluronic acid-polypeptide conjugate is obtained. According to the technical scheme, the auxin can be perfectly connected to the hyaluronic acid, and the binding rate is about 70%; the secondary structure of the auxin in the hyaluronic acid-polypeptide conjugate disclosed by the invention is not changed; and in a skin tissue test, the hyaluronic acid-polypeptide conjugate can be effectively transferred to a corium layer.